urea has been researched along with Hyperuricemia in 20 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperuricemia is associated with aortic dissection and cardiovascular diseases." | 5.72 | Post-operative uric acid: a predictor for 30-days mortality of acute type A aortic dissection repair. ( Chen, X; Hu, Q; Huang, L; Lin, G; Luo, W; Ma, S; Wu, D; Xu, Q, 2022) |
| "Hyperuricemia is defined by the European Rheumatology Society as a uric acid level greater than 6 mg/dl (60 mg/l or 360 μmol/l)." | 4.02 | Creation of an adequate animal model of hyperuricemia (acute and chronic hyperuricemia); study of its reversibility and its maintenance. ( Affes, H; Charfi, S; Dhouibi, R; Hammami, S; Jamoussi, K; Ksouda, K; Marekchi, R; Moalla, D; Sahnoun, Z; Salem, MB; Zeghal, KM, 2021) |
| " Significant changes of biochemical parameters in cases of hypertensive disorders in pregnancy are increased levels of blood glucose, urea, creatinine, uric acid (hyperuricemia), transaminases, and LDH." | 3.79 | Correlation of biochemical parameters and neonatal outcome in patients with gestational hypertension. ( Aksam, S; Kocijancic, A; Kocijancic, DM; Plecas, D; Plesinac, S, 2013) |
| "Hyperuricemia is associated with aortic dissection and cardiovascular diseases." | 1.72 | Post-operative uric acid: a predictor for 30-days mortality of acute type A aortic dissection repair. ( Chen, X; Hu, Q; Huang, L; Lin, G; Luo, W; Ma, S; Wu, D; Xu, Q, 2022) |
| "Triuret was also found to be elevated in the urine of subjects with preeclampsia, a pregnancy-specific hypertensive syndrome that is associated with oxidative stress, whereas very little triuret is produced in normal healthy volunteers." | 1.35 | Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. ( Angerhofer, A; Gersch, C; Henderson, GN; Imaram, W; Johnson, RJ; Karumanchi, SA; Kim, KM; Palii, SP, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 9 (45.00) | 2.80 |
| Authors | Studies |
|---|---|
| ALRashdi, BM | 1 |
| Elgebaly, HA | 1 |
| Germoush, MO | 1 |
| Qarmush, MM | 1 |
| Azab, MS | 1 |
| Alruhaimi, RS | 1 |
| Ahmeda, AF | 1 |
| Abukhalil, MH | 1 |
| Kamel, EM | 1 |
| Arab, HH | 1 |
| Alzoghaibi, MA | 1 |
| Alotaibi, MF | 1 |
| Mahmoud, AM | 1 |
| Huang, L | 2 |
| He, X | 2 |
| Peng, W | 1 |
| Xu, B | 1 |
| Xu, H | 1 |
| Wang, Y | 2 |
| Xu, W | 1 |
| Chen, W | 1 |
| Wang, S | 1 |
| Zhou, L | 1 |
| Liu, N | 1 |
| Xu, Y | 1 |
| Lu, W | 1 |
| Wang, M | 1 |
| Zhuoma, D | 1 |
| Yuan, R | 1 |
| Pu, Z | 1 |
| Zeren, L | 1 |
| Wang, J | 1 |
| Tan, M | 1 |
| Huang, S | 1 |
| Ma, S | 1 |
| Xu, Q | 1 |
| Hu, Q | 1 |
| Wu, D | 1 |
| Lin, G | 1 |
| Chen, X | 1 |
| Luo, W | 1 |
| Li, N | 4 |
| Amatjan, M | 4 |
| He, P | 4 |
| Zhang, B | 4 |
| Mai, X | 4 |
| Jiang, Q | 4 |
| Xie, H | 4 |
| Shao, X | 4 |
| Huang, XF | 1 |
| He, Q | 1 |
| Shi, HH | 1 |
| Hu, HP | 1 |
| Lu, L | 1 |
| Huang, RM | 1 |
| Zhang, XY | 1 |
| Xu, YQ | 1 |
| Wahba, NS | 1 |
| Abdel-Ghany, RH | 1 |
| Ghareib, SA | 1 |
| Abdel-Aal, M | 1 |
| Alsemeh, AE | 1 |
| Dhouibi, R | 1 |
| Affes, H | 1 |
| Salem, MB | 1 |
| Moalla, D | 1 |
| Marekchi, R | 1 |
| Charfi, S | 1 |
| Hammami, S | 1 |
| Sahnoun, Z | 1 |
| Jamoussi, K | 1 |
| Zeghal, KM | 1 |
| Ksouda, K | 1 |
| Kemter, E | 1 |
| Prueckl, P | 1 |
| Sklenak, S | 1 |
| Rathkolb, B | 1 |
| Habermann, FA | 1 |
| Hans, W | 1 |
| Gailus-Durner, V | 1 |
| Fuchs, H | 1 |
| Hrabě de Angelis, M | 1 |
| Wolf, E | 1 |
| Aigner, B | 1 |
| Wanke, R | 1 |
| Zhang, YF | 1 |
| He, F | 1 |
| Ding, HH | 1 |
| Dai, W | 1 |
| Zhang, Q | 1 |
| Luan, H | 1 |
| Lv, YM | 1 |
| Zeng, HB | 1 |
| Gersch, C | 1 |
| Palii, SP | 1 |
| Imaram, W | 1 |
| Kim, KM | 1 |
| Karumanchi, SA | 1 |
| Angerhofer, A | 1 |
| Johnson, RJ | 1 |
| Henderson, GN | 1 |
| Kocijancic, DM | 1 |
| Plesinac, S | 1 |
| Plecas, D | 1 |
| Aksam, S | 1 |
| Kocijancic, A | 1 |
| Krauss, M | 1 |
| Schaller, S | 1 |
| Borchers, S | 1 |
| Findeisen, R | 1 |
| Lippert, J | 1 |
| Kuepfer, L | 1 |
| Huang, CT | 1 |
| Chen, ML | 1 |
| Huang, LL | 1 |
| Mao, IF | 1 |
| MCKECHNIE, JK | 1 |
| ALPERIN, JB | 1 |
| LEVIN, WC | 1 |
| HOEFNAGEL, D | 1 |
| KRAKOFF, IH | 1 |
| MEYER, RL | 1 |
| Ganson, NJ | 1 |
| Kelly, SJ | 1 |
| Scarlett, E | 1 |
| Sundy, JS | 1 |
| Hershfield, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alternative Haemodiafiltration in Summer Season for Chronic Kidney Disease Patients[NCT05861219] | 100 participants (Anticipated) | Interventional | 2023-06-21 | Not yet recruiting | |||
| Using of the Skin as a Third Spare Kidney for Patients With Chronic Renal Failure[NCT03810989] | 86 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | |||
| A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout[NCT00111657] | Phase 2 | 30 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients who developed antibodies to PEG-uricase (NCT00111657)
Timeframe: baseline, then prior to infusions and 7 wks after last infusion
| Intervention | participants (Number) |
|---|---|
| Pegloticase | 15 |
The highest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 2 hours
| Intervention | mU/mL (Mean) |
|---|---|
| Single Arm - Pegloticase | 25.6 |
The lowest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 21 days after the infusion
| Intervention | mU/mL (Mean) |
|---|---|
| Single Arm - Pegloticase | 4.9 |
(NCT00111657)
Timeframe: Baseline to Day 105
| Intervention | Participants (Number) |
|---|---|
| Single Arm | 17 |
Count of tenderness and swelling of 68 joints (NCT00111657)
Timeframe: Basline and day 134
| Intervention | joints (Median) | |||
|---|---|---|---|---|
| Number of Tender joints at baseline | Number of Tender joints at day 134 | Number of Swollen jonts at baseline | Number of Swollen jonts at day 134 | |
| Pegloticase | 13 | 2 | 9 | 6 |
1 review available for urea and Hyperuricemia
| Article | Year |
|---|---|
Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis.
Topics: Blood Pressure; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperur | 2014 |
1 trial available for urea and Hyperuricemia
| Article | Year |
|---|---|
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Topics: Adult; Aged; Carbon Radioisotopes; Female; Gout; Humans; Hyperuricemia; Immunoglobulin G; Male; Midd | 2006 |
18 other studies available for urea and Hyperuricemia
| Article | Year |
|---|---|
A flavonoid-rich fraction of Monolluma quadrangula inhibits xanthine oxidase and ameliorates potassium oxonate-induced hyperuricemia in rats.
Topics: Animals; Catalase; Creatinine; Cytokines; Flavonoids; Hyperuricemia; Inflammation; Kidney; Molecular | 2022 |
Hyperuricemia induces liver injury by upregulating HIF-1α and inhibiting arginine biosynthesis pathway in mouse liver and human L02 hepatocytes.
Topics: Animals; Arginine; Argininosuccinate Synthase; Hepatocytes; Humans; Hyperuricemia; Hypoxia-Inducible | 2022 |
Ethanol extract of Nepeta angustifoia C. Y. Wu ameliorates hyperuricemia in fructose-induced mice.
Topics: Animals; Creatinine; Drugs, Chinese Herbal; Ethanol; Fructose; Hyperuricemia; Kidney; Mice; Nepeta; | 2022 |
Post-operative uric acid: a predictor for 30-days mortality of acute type A aortic dissection repair.
Topics: Aortic Dissection; Creatinine; Fibrinogen; Humans; Hyperuricemia; Retrospective Studies; Urea; Uric | 2022 |
Integration of network pharmacology and intestinal flora to investigate the mechanism of action of Chinese herbal
Topics: Adenine; Animals; China; Cichorium intybus; Ethambutol; Gastrointestinal Microbiome; Hyperuricemia; | 2022 |
Integration of network pharmacology and intestinal flora to investigate the mechanism of action of Chinese herbal
Topics: Adenine; Animals; China; Cichorium intybus; Ethambutol; Gastrointestinal Microbiome; Hyperuricemia; | 2022 |
Integration of network pharmacology and intestinal flora to investigate the mechanism of action of Chinese herbal
Topics: Adenine; Animals; China; Cichorium intybus; Ethambutol; Gastrointestinal Microbiome; Hyperuricemia; | 2022 |
Integration of network pharmacology and intestinal flora to investigate the mechanism of action of Chinese herbal
Topics: Adenine; Animals; China; Cichorium intybus; Ethambutol; Gastrointestinal Microbiome; Hyperuricemia; | 2022 |
A Novel Approach Based on Gut Microbiota Analysis and Network Pharmacology to Explain the Mechanisms of Action of
Topics: Adenine; Animals; Cichorium intybus; Creatinine; Drugs, Chinese Herbal; Ethambutol; Gastrointestinal | 2023 |
[Mediating effects of obesity and metabolic factors in hyperuricemia and prehypertension].
Topics: Body Mass Index; Cholesterol; Cholesterol, LDL; Creatinine; Humans; Hyperuricemia; Nitrogen; Obesity | 2023 |
Vitamin D3 potentiates the renoprotective effects of vildagliptin in a rat model of fructose/salt-induced insulin resistance.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Cholecalciferol; Creatinine; Dipeptidyl-Pepti | 2020 |
Creation of an adequate animal model of hyperuricemia (acute and chronic hyperuricemia); study of its reversibility and its maintenance.
Topics: Animals; Antioxidants; Biomarkers; Chronic Disease; Creatinine; Disease Models, Animal; Hyperuricemi | 2021 |
Type of uromodulin mutation and allelic status influence onset and severity of uromodulin-associated kidney disease in mice.
Topics: Age of Onset; Alleles; Animals; Body Weight; Cystatins; Disease Models, Animal; Disease Progression; | 2013 |
Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress.
Topics: Antioxidants; Female; Humans; Hyperuricemia; Oxidants; Oxidative Stress; Peroxynitrous Acid; Pre-Ecl | 2009 |
Correlation of biochemical parameters and neonatal outcome in patients with gestational hypertension.
Topics: Apgar Score; Blood Glucose; Case-Control Studies; Creatinine; Female; HELLP Syndrome; Humans; Hypert | 2013 |
Integrating cellular metabolism into a multiscale whole-body model.
Topics: Acetaminophen; Allopurinol; Ammonia; Chemical and Drug Induced Liver Injury; Computational Biology; | 2012 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
GOUT, HYPERURICAEMIA AND CARBOHYDRATE METABOLISM.
Topics: Carbohydrate Metabolism; Cholesterol; Glucose Tolerance Test; Gout; Humans; Hypertension; Hyperurice | 1964 |
EXTREME HYPERURICEMIA ASSOCIATED WITH PREDNISONE THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA.
Topics: Adolescent; Blood; Blood Urea Nitrogen; Humans; Hyperuricemia; Leukemia; Leukemia, Lymphoid; Lymphoc | 1964 |
THE SYNDROME OF ATHETOID CEREBRAL PALSY, MENTAL DEFICIENCY, SELF-MUTILATION AND HYPERURICEMIA.
Topics: Athetosis; Blood Chemical Analysis; Blood Urea Nitrogen; Cerebral Palsy; Child; Genetics, Medical; H | 1965 |
PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA: USE OF ALOPURINOL, A XANTHINE OXIDASE INHIBITOR.
Topics: Adolescent; Antineoplastic Agents; Blood; Blood Urea Nitrogen; Drug Therapy; Geriatrics; Humans; Hyp | 1965 |